Arrayit(OTC) ARYC

Arrayit Corporation is a global life sciences technology firm based in Sunnyvale, California. The company specializes in developing and commercializing advanced tools for genetic analysis and diagnostic applications.

Products and Services

• Microarray instruments and components for genetic analysis
• Custom microarray printing and analysis services
• Diagnostic microarrays for early health condition identification

Growth Outlook

• Innovative microarray technology supports diverse research applications
• Expanding client base includes genomic research centers and pharmaceutical companies
• Potential for increased demand in diagnostics and personalized medicine

Financial Highlights

• Recent quarterly revenue of 615,151, showing growth potential
• Gross profit margin of 60.32% indicates strong product demand
• Operating cash flow trends suggest ongoing operational challenges

Arrayit Corporation operates in the medical diagnostics and research industry, focusing on advanced genetic analysis tools. The company’s product offerings include a range of microarray instruments, which are essential for various research and diagnostic applications. The innovative technology allows for the production of diverse microarray types, catering to a wide array of scientific needs. The growth outlook for Arrayit Corporation appears promising, driven by the increasing demand for genetic analysis and diagnostics. The company serves a broad spectrum of clients, including academic institutions and biotechnology firms, which positions it well for future expansion. As the healthcare industry increasingly shifts towards personalized medicine, Arrayit’s capabilities in microarray technology may become even more critical. Financially, the company reported a recent quarterly revenue of 615,151, reflecting its potential for growth. The gross profit margin of 60.32% indicates a strong demand for its products, although operational challenges remain evident in cash flow trends. Overall, Arrayit Corporation presents an intriguing opportunity within the life sciences sector, particularly for those interested in the evolving landscape of genetic diagnostics.